Top

Current Fungal Infection Reports

Published in:

01-03-2018 | Epidemiology of Fungal Infections (T Chiller and JW Baddley, Section Editors)

A Case for Antifungal Stewardship

Author: Rachel A. Miller

Published in: Current Fungal Infection Reports | Issue 1/2018

Abstract

Purpose of Review

The expanding utilization of limited available antifungal agents has led to a pressing need to implement interventions to ensure appropriate usage. The global emergence of resistant, difficult-to-treat invasive fungal infections among the most vulnerable patient populations is a call to action to develop a multifaceted antifungal stewardship approach.

Recent Findings

Candida species demonstrating multi-drug resistance, including highly resistant Candida auris, are emerging threats. Azole-resistant Aspergillus fumigatus, likely initially originating in the environment, likewise presents a treatment challenge. Routine empiric and prophylactic antifungal use, though effective, further complicates this issue, with the emergence of breakthrough mold infections. Early evidence supports success with antifungal stewardship programs.

Summary

Broad antifungal stewardship approaches that optimize antifungal drug usage, facilitate provider education, and monitor fungal epidemiology are crucial steps to preserve the antifungal armamentarium. Future development of novel diagnostic and treatment strategies will further facilitate management of invasive fungal infections.

Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13. https://doi.org/10.1126/scitranslmed.3004404.CrossRefPubMed

Munoz P, Bouza E, group Cs. The current treatment landscape: the need for antifungal stewardship programmes. J Antimicrob Chemother. 2016;71(suppl 2):ii5–ii12. https://doi.org/10.1093/jac/dkw391.CrossRefPubMed

•• Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362–8. https://doi.org/10.1093/cid/civ885. A comprehensive overview of azole resistance in Aspergillus fumigatus and its global health consequences. CrossRefPubMed

•• Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–40. https://doi.org/10.1093/cid/ciw691. Epidemiologic and susceptibility characterization of 54 C. auris isolates obtained worldwide, which demonstrate frequent nosocomial transmission, multi-drug resistance, and high mortality. CrossRefPubMed

• Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis. 2017;64(11):1619–21. https://doi.org/10.1093/cid/cix130. The largest published cohort characterizing the epidemiology of breakthrough invasive mold infections in the setting of azole prophylaxis over a 4 year period. CrossRefPubMed

Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445–S51. https://doi.org/10.1093/infdis/jix131.CrossRefPubMed

•• Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017; https://doi.org/10.1016/S1473-3099(17)30316-X. An overview of antifungal resistance, including mechanisms, epidemiologic risk factors, and general guidelines for antifungal stewardship.

Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, Passweg J, et al. Multispecific aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis. 2015;211(8):1251–61. https://doi.org/10.1093/infdis/jiu607.CrossRefPubMed

Chowdhary A, Sharma C, Meis JF. Azole-resistant Aspergillosis: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S436–S44. https://doi.org/10.1093/infdis/jix210.CrossRefPubMed

10.

Mueller-Loebnitz C, Ostermann H, Franzke A, Loeffler J, Uharek L, Topp M, et al. Immunological aspects of Candida and Aspergillus systemic fungal infections. Interdiscip Perspect Infect Dis. 2013;2013:102934. https://doi.org/10.1155/2013/102934.CrossRefPubMedPubMedCentral

11.

Perlin DS, Wiederhold NP. Culture-independent molecular methods for detection of antifungal resistance mechanisms and fungal identification. J Infect Dis. 2017;216(suppl_3):S458–S65. https://doi.org/10.1093/infdis/jix121.CrossRefPubMed

12.

• Valerio M, Rodriguez-Gonzalez CG, Munoz P, Caliz B, Sanjurjo M, Bouza E, et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother. 2014;69(7):1993–9. https://doi.org/10.1093/jac/dku053. An institutional assessment of the quality of use of antifungal agents, with an estimate of potential cost savings to support establishment of an antifungal stewardship program. CrossRefPubMed

13.

Nivoix Y, Launoy A, Lutun P, Moulin JC, Phai Pang KA, Fornecker LM, et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother. 2012;67(10):2506–13. https://doi.org/10.1093/jac/dks256.CrossRefPubMed

14.

Sutepvarnon A, Apisarnthanarak A, Camins B, Mondy K, Fraser VJ. Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study. Infect Control Hosp Epidemiol. 2008;29(4):370–3. https://doi.org/10.1086/587633.CrossRefPubMed

15.

Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant. 2008;8(2):426–31. https://doi.org/10.1111/j.1600-6143.2007.02089.x.CrossRefPubMed

16.

Munoz P, Rojas L, Cervera C, Garrido G, Farinas MC, Valerio M, et al. Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clin Transpl. 2012;26(1):87–96. https://doi.org/10.1111/j.1399-0012.2011.01405.x.CrossRef

17.

van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013;57(4):513–20. https://doi.org/10.1093/cid/cit320.CrossRefPubMed

18.

• Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. Am J Transplant. 2017;17(1):296–9. https://doi.org/10.1111/ajt.14121. The first description of C. auris isolates in the United States and their relatedness to isolates from South America and South Asia. CrossRefPubMed

19.

Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5–10. https://doi.org/10.1111/1469-0691.12539.CrossRef

20.

Bassetti M, Peghin M, Timsit JF. The current treatment landscape: candidiasis. J Antimicrob Chemother. 2016;71(suppl 2):ii13–22. https://doi.org/10.1093/jac/dkw392.CrossRefPubMed

21.

Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359(9312):1135–44. https://doi.org/10.1016/S0140-6736(02)08162-X.CrossRefPubMed

22.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366–77. https://doi.org/10.1128/JCM.02117-09.CrossRefPubMedPubMedCentral

23.

Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis. 2010;66(4):373–84. https://doi.org/10.1016/j.diagmicrobio.2009.11.006.CrossRefPubMed

24.

Morschhauser J. The development of fluconazole resistance in Candida albicans—an example of microevolution of a fungal pathogen. J Microbiol. 2016;54(3):192–201. https://doi.org/10.1007/s12275-016-5628-4.CrossRefPubMed

25.

Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother. 2012;56(5):2435–42. https://doi.org/10.1128/AAC.06369-11.CrossRefPubMedPubMedCentral

26.

Hull CM, Bader O, Parker JE, Weig M, Gross U, Warrilow AG, et al. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Chemother. 2012;56(12):6417–21. https://doi.org/10.1128/AAC.01145-12.CrossRefPubMedPubMedCentral

27.

Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother. 2010;54(9):3578–83. https://doi.org/10.1128/AAC.00303-10.CrossRefPubMedPubMedCentral

28.

Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun. 2016;7:11128. https://doi.org/10.1038/ncomms11128.CrossRefPubMedPubMedCentral

29.

Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445–56. https://doi.org/10.1056/NEJMra1315399.CrossRefPubMed

30.

• Bailly S, Maubon D, Fournier P, Pelloux H, Schwebel C, Chapuis C, et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp.—trends over 10 years. J Infect. 2016;72(1):103–11. https://doi.org/10.1016/j.jinf.2015.09.041. A 10 year retrospective study correlating ICU antifungal use with Candida species distribution and antifungal susceptibility profiles. CrossRefPubMed

31.

Fekkar A, Meyer I, Brossas JY, Dannaoui E, Palous M, Uzunov M, et al. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother. 2013;57(5):2380–2. https://doi.org/10.1128/AAC.02037-12.CrossRefPubMedPubMedCentral

32.

Asner SA, Giulieri S, Diezi M, Marchetti O, Sanglard D. Acquired multidrug antifungal resistance in Candida lusitaniae during therapy. Antimicrob Agents Chemother. 2015;59(12):7715–22. https://doi.org/10.1128/AAC.02204-15.CrossRefPubMedPubMedCentral

33.

Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. Uncommon Candida species Fungemia among cancer patients, Houston, Texas. USA Emerg Infect Dis. 2015;21(11):1942–50. https://doi.org/10.3201/eid2111.150404.PubMed

34.

Dufresne SF, Marr KA, Sydnor E, Staab JF, Karp JE, Lu K, et al. Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol. 2014;52(6):1830–7. https://doi.org/10.1128/JCM.00131-14.CrossRefPubMedPubMedCentral

35.

Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis. 2014;20(11):1833–40. https://doi.org/10.3201/eid2011.140685.CrossRefPubMedPubMedCentral

36.

Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014;59(6):819–25. https://doi.org/10.1093/cid/ciu407.CrossRefPubMed

37.

Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–32. https://doi.org/10.1093/cid/cit136.CrossRefPubMedPubMedCentral

38.

Tsay S, Welsh RM, Adams EH, Chow NA, Gade L, Berkow EL, et al. Notes from the field: ongoing transmission of Candida auris in health care facilities—United States, June 2016–May 2017. MMWR Morb Mortal Wkly Rep. 2017;66(19):514–5. https://doi.org/10.15585/mmwr.mm6619a7.CrossRefPubMedPubMedCentral

39.

Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Inf Secur. 2016;73(4):369–74. https://doi.org/10.1016/j.jinf.2016.07.008.

40.

Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35. https://doi.org/10.1186/s13756-016-0132-5.CrossRefPubMedPubMedCentral

41.

Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56(9):4862–9. https://doi.org/10.1128/AAC.00027-12.CrossRefPubMedPubMedCentral

42.

Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010;48(7):2373–80. https://doi.org/10.1128/JCM.02390-09.CrossRefPubMedPubMedCentral

43.

Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 2014;9(5):697–711. https://doi.org/10.2217/fmb.14.27.CrossRefPubMed

44.

Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356(14):1481–3. https://doi.org/10.1056/NEJMc061720.CrossRefPubMed

45.

Wiederhold NP, Patterson TF. Emergence of azole resistance in Aspergillus. Semin Respir Crit Care Med. 2015;36(5):673–80. https://doi.org/10.1055/s-0035-1562894.CrossRefPubMed

46.

Hagiwara D, Watanabe A, Kamei K, Goldman GH. Epidemiological and genomic landscape of azole resistance mechanisms in Aspergillus fungi. Front Microbiol. 2016;7:1382. https://doi.org/10.3389/fmicb.2016.01382.CrossRefPubMedPubMedCentral

47.

Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, Huynen MA, et al. Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One. 2012;7(11):e50034. https://doi.org/10.1371/journal.pone.0050034.CrossRefPubMedPubMedCentral

48.

Rajendran R, Mowat E, McCulloch E, Lappin DF, Jones B, Lang S, et al. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother. 2011;55(5):2092–7. https://doi.org/10.1128/AAC.01189-10.CrossRefPubMedPubMedCentral

49.

Jasinski M, Ducos E, Martinoia E, Boutry M. The ATP-binding cassette transporters: structure, function, and gene family comparison between rice and Arabidopsis. Plant Physiol. 2003;131(3):1169–77. https://doi.org/10.1104/pp.102.014720.CrossRefPubMedPubMedCentral

50.

Azevedo MM, Faria-Ramos I, Cruz LC, Pina-Vaz C, Rodrigues AG. Genesis of azole antifungal resistance from agriculture to clinical settings. J Agric Food Chem. 2015;63(34):7463–8. https://doi.org/10.1021/acs.jafc.5b02728.CrossRefPubMed

51.

• Berger S, El Chazli Y, Babu AF, Coste AT. Azole resistance in aspergillus fumigatus: a consequence of antifungal use in agriculture? Front Microbiol. 2017;8:1024. https://doi.org/10.3389/fmicb.2017.01024. A mini-review discussing the emergence of azole resistant Aspergillus fumigatus in the setting of agricultural antifungal use. CrossRefPubMedPubMedCentral

52.

Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9(10):e1003633. https://doi.org/10.1371/journal.ppat.1003633.CrossRefPubMedPubMedCentral

53.

Snelders E, Camps SM, Karawajczyk A, Schaftenaar G, Kema GH, van der Lee HA, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One. 2012;7(3):e31801. https://doi.org/10.1371/journal.pone.0031801.CrossRefPubMedPubMedCentral

54.

Verweij PE, Kema GH, Zwaan B, Melchers WJ. Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Manag Sci. 2013;69(2):165–70. https://doi.org/10.1002/ps.3390.CrossRefPubMed

55.

van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 2011;17(10):1846–54. https://doi.org/10.3201/eid1710.110226.CrossRefPubMedPubMedCentral

56.

Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5(11):e219. https://doi.org/10.1371/journal.pmed.0050219.CrossRefPubMedPubMedCentral

57.

•• van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21(6):1041–4. https://doi.org/10.3201/eid2106.140717. A prospective study to assess global azole resistance among A. fumigatus isolates involving 22 centers in 19 countries. CrossRefPubMedPubMedCentral

58.

Hagiwara D, Takahashi H, Fujimoto M, Sugahara M, Misawa Y, Gonoi T, et al. Multi-azole resistant Aspergillus fumigatus harboring Cyp51A TR46/Y121F/T289A isolated in Japan. J Infect Chemother. 2016;22(8):577–9. https://doi.org/10.1016/j.jiac.2016.01.015.CrossRefPubMed

59.

Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011;55(9):4465–8. https://doi.org/10.1128/AAC.00185-11.CrossRefPubMedPubMedCentral

60.

Arauz AB, Caceres DH, Santiago E, Armstrong P, Arosemena S, Ramos C, et al. Isolation of Candida auris from 9 patients in central America: importance of accurate diagnosis and susceptibility testing. Mycoses. 2017; https://doi.org/10.1111/myc.12709.

61.

• Wiederhold NP, Gil VG, Gutierrez F, Lindner JR, Albataineh MT, McCarthy DI, et al. First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States. J Clin Microbiol. 2016;54(1):168–71. https://doi.org/10.1128/JCM.02478-15. The first report of 26 cyp51A mutations in A. fumigatus isolates identified in the US, with isolates dating back to 2001. CrossRefPubMed

62.

Dunne K, Hagen F, Pomeroy N, Meis JF, Rogers TR. Intercountry transfer of triazole-resistant aspergillus fumigatus on plant bulbs. Clin Infect Dis. 2017;65(1):147–9. https://doi.org/10.1093/cid/cix257.CrossRefPubMed

63.

van Paassen J, Russcher A, In 't Veld-van Wingerden AW, Verweij PE, Kuijper EJ. Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. Euro Surveill. 2016;21(30):1–9. https://doi.org/10.2807/1560-7917.ES.2016.21.30.30300.

64.

Heo ST, Tatara AM, Jimenez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, et al. Changes in in vitro susceptibility patterns of aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center, 1999-2015. Clin Infect Dis. 2017;65(2):216–25. https://doi.org/10.1093/cid/cix297.CrossRefPubMed

65.

Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis. 2006;55(3):209–12. https://doi.org/10.1016/j.diagmicrobio.2006.01.018.CrossRefPubMed

66.

Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother. 2012;67(9):2268–73. https://doi.org/10.1093/jac/dks189.CrossRefPubMed

67.

Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71(9):2634–41. https://doi.org/10.1093/jac/dkw199.CrossRefPubMed

68.

Corzo-Leon DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses. 2015;58(6):325–36. https://doi.org/10.1111/myc.12318.CrossRefPubMed

69.

Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014;20(11):O952–9. https://doi.org/10.1111/1469-0691.12688.CrossRefPubMed

70.

Fuhren J, Voskuil WS, Boel CH, Haas PJ, Hagen F, Meis JF, et al. High prevalence of azole resistance in aspergillus fumigatus isolates from high-risk patients. J Antimicrob Chemother. 2015;70(10):2894–8. https://doi.org/10.1093/jac/dkv177.CrossRefPubMed

71.

Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Bruggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21–22:30–40. https://doi.org/10.1016/j.drup.2015.08.001.CrossRefPubMed

72.

•• Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. Virulence. 2017;8(6):658–72. https://doi.org/10.1080/21505594.2016.1226721. A comprehensive review discussing necessary components and impediments to establishing an antifungal stewardship program. CrossRefPubMed

73.

Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D, Enoch DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge. Engl J Antimicrob Chemother. 2015;70(6):1908–11. https://doi.org/10.1093/jac/dkv040.

74.

Mondain V, Lieutier F, Hasseine L, Gari-Toussaint M, Poiree M, Lions C, et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection. 2013;41(3):621–8. https://doi.org/10.1007/s15010-013-0431-1.CrossRefPubMed

75.

Lopez-Medrano F, San Juan R, Lizasoain M, Catalan M, Ferrari JM, Chaves F, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013;19(1):56–61. https://doi.org/10.1111/j.1469-0691.2012.03891.x.CrossRefPubMed

76.

Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24–34. https://doi.org/10.1128/AAC.00705-08.CrossRefPubMed

77.

Bal AM, Shankland GS, Scott G, Imtiaz T, Macaulay R, McGill M. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. Int J Clin Pract. 2014;68(1):20–7. https://doi.org/10.1111/ijcp.12231.CrossRefPubMed

78.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. https://doi.org/10.1093/cid/civ933.CrossRefPubMed

79.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66(9):2146–51. https://doi.org/10.1093/jac/dkr244.CrossRefPubMed

80.

Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51–77. https://doi.org/10.1093/cid/ciw118.CrossRefPubMedPubMedCentral

81.

Cassone A, Casadevall A. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol. 2012;15(4):427–33. https://doi.org/10.1016/j.mib.2012.04.004.CrossRefPubMedPubMedCentral

82.

Santos E, Levitz SM. Fungal vaccines and immunotherapeutics. Cold Spring Harb Perspect Med. 2014;4(11):a019711. https://doi.org/10.1101/cshperspect.a019711.CrossRefPubMedPubMedCentral

83.

Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A. 2014;111(29):10660–5. https://doi.org/10.1073/pnas.1312789111.CrossRefPubMedPubMedCentral

84.

Saracli MA, Fothergill AW, Sutton DA, Wiederhold NP. Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Med Mycol. 2015;53(7):736–42. https://doi.org/10.1093/mmy/myv046.CrossRefPubMed

85.

Atkins SD, Clark IM. Fungal molecular diagnostics: a mini review. J Appl Genet. 2004;45(1):3–15.PubMed

86.

Wengenack NL, Binnicker MJ. Fungal molecular diagnostics. Clin Chest Med. 2009;30(2):391–408, viii. https://doi.org/10.1016/j.ccm.2009.02.014.CrossRefPubMed

87.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. https://doi.org/10.1093/cid/ciw326.CrossRefPubMedPubMedCentral

Title: A Case for Antifungal Stewardship
Author: Rachel A. Miller
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Fungal Infection Reports / Issue 1/2018
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-018-0307-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Antifungal Dosing Considerations in Patients Undergoing Continuous Renal Replacement Therapy

Pathogenesis and Pathology of Invasive Aspergillosis

Emergomyces: a New Genus of Dimorphic Fungal Pathogens Causing Disseminated Disease among Immunocompromised Persons Globally

Challenges in the Diagnosis of Invasive Fungal Infections in Immunocompromised Hosts

Epidemiology of Histoplasmosis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage